http://www.forbes.com/business/2007/04/26/dendreon-provenge-prostate-biz-cx_mh_0426dendreon.htmlposted at 1 PM... coincidental with the 8% plus drop...stones of steel, here we come. didnt realize scher was a bigshot at sloan-kettering, his opinion wields a bigger sword to me now. advantage is that DNDN will probably drop below my $15 average share price. yay! i can buy more soon enough on the cheap.
I read somewhere that members of the AC that have a minority opinion, against the vote are supposed to send a letter to the FDA expressing their concerns. I don't know if this is true, but if so the only thing out of the ordinary is leaking of this information to the public. Since it has happened twice, to the same Cancer Letter it probably is coming from inside the FDA. Lots of FDA insiders probably know about the letters, but few know about the FDA final decision, which is made by very few people at the top. It's just another Bear tool used to frighten investors. It seems to be working, at least for today.
15 is short term support, and today's fall is on relatively light volume, so I don't think there's a big chance of falling below that number. If it gets to 12 or 11, maybe I'll buy more.
Best Of |
Favorites & Replies |
Start a New Board |
My Fool |
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ra